Huadong Medicine: Exclusive distribution product injectable recombinant Botulinum Toxin Type A approved for market launch

2026-03-27 11:01:47

On March 27, People’s Financial News reported that East China Pharmaceutical (000963) announced on March 27 that its exclusive distribution product, injectable recombinant botulinum toxin type A (brand name: Ruitoxin®), has been approved by the National Medical Products Administration for market launch. It is used for the temporary improvement of moderate to severe glabellar lines in adults aged 65 and below due to the activity of the corrugator and/or procerus muscles.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.